
|Articles|January 1, 2008
Updated Disease Management Guidelines Impact Investment Perspectives
Disease management programs don't come cheap, but thanks to industry collaboration, purchasers are increasingly learning how to assess the business case for these programs.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Review calls for combining outcome measures for hidradenitis suppurativa treatment
2
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
3
States push for new PBM reporting rules | PBMI 2026
4
Transparency is out. Actionable data is in. | PBMI 2026
5
















